ClinicalTrials.Veeva

Menu

Validation of a 13C Glucose Breath Test Compared With the Euglycaemic Clamp Test (BRECLAIR)

A

Antwerp University Hospital (UZA)

Status

Unknown

Conditions

Type 1 Diabetes
Insulin Resistance

Treatments

Diagnostic Test: 13C glucose breath test
Diagnostic Test: euglycaemic clamp test

Study type

Observational

Funder types

Other

Identifiers

NCT04623320
20/40/515

Details and patient eligibility

About

Insulin resistance can be assessed by the euglycaemic clamp technique. To date, this is the golden standard, but it is not suited for clinical practice. A 13C glucose breath test will be tested as a valid alternative. The curve of the exhaled 13C CO2 as a function of glucose metabolism can be correlated to the curve of the glucose disposal rate obtained via the clamp technique.

Full description

The hyperinsulinemic-euglycemic clamp technique is the golden standard to assess insulin resistance in type 1 diabetes subjects. The plasma insulin concentration is acutely raised and maintained at 100 μU/ml by a continuous infusion of insulin. Meanwhile, the plasma glucose concentration is held constant at basal levels by a variable glucose infusion. When the steady-state is achieved, the glucose infusion rate equals glucose uptake by all the tissues in the body and is therefore a measure of tissue insulin sensitivity.

These data will be compared with the results of a 13C glucose breath test. Breath tests using 13C substrates are based on the principle that 13C CO2 in the exhaled breath can be measured as a metabolic tracer.

Breath testing has a major advantage over the clamp test in that it can be performed non-invasively and repeatedly without necessary supervision by medical staff.

Enrollment

50 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult type 1 diabetes patients
  • 25/50 subjects with confirmed NAFLD (using ultrasound criteria)

Exclusion criteria

  • pregnancy
  • gastric bypass surgery
  • cirrhosis
  • secondary cause of liver steatosis present
  • any cause which makes a 4-hour clamp impossible

Trial design

50 participants in 2 patient groups

NAFLD+T1DM+
Description:
Subjects with type 1 diabetes and ultrasound-defined NAFLD
Treatment:
Diagnostic Test: 13C glucose breath test
Diagnostic Test: euglycaemic clamp test
NAFLD-T1DM+
Description:
Subjects with type 1 diabetes without ultrasound-defined NAFLD
Treatment:
Diagnostic Test: 13C glucose breath test
Diagnostic Test: euglycaemic clamp test

Trial contacts and locations

1

Loading...

Central trial contact

Maria Braspenning, nurse; Jonathan Mertens, M.D.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems